ViaCyte acquires rights to BetaLogics assets from Janssen
ViaCyte and Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have agreed to consolidate the assets of the Janssen BetaLogics group into ViaCyte. The agreement provides ViaCyte with an exclusive license to all BetaLogics intellectual property in the field of metabolic disease, including diabetes, and the transfer of related assets to ViaCyte.
Click on this link for more information.
